SCHEMBL3489669

SCHEMBL3489669

Cc1c(B2OC(C)(C)C(C)(C)O2)ccc2c1NC(=O)CO2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 1/20 0.48
MMP12 P39900 1/20 0.42
PARP1 P09874 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.33
DRD2 P14416 3/20 0.33
DRD4 P21917 3/20 0.33
DRD3 P35462 2/20 0.33
MTNR1A P48039 1/20 0.33
MTNR1B P49286 1/20 0.33
ALDH1A1 P00352 2/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MAP4K1 Q92918 1/20 0.32
PKM P14618 3/20 0.32
JAK2 O60674 3/20 0.32
BTK Q06187 3/20 0.32
MAPK1 P28482 1/20 0.32
GRM5 P41594 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3489569 0.85 NR3C2 (0.39) NR3C2MMP12PARP1SMN1; SMN2MTNR1A
SCHEMBL3488307 0.85 NR3C2 (0.39) NR3C2MMP12PARP1SMN1; SMN2DRD2
SCHEMBL6432532 0.77 NR3C2 (0.56) NR3C2MMP12PARP1SMN1; SMN2MTNR1A
SCHEMBL21493568 0.76 CA9 (0.33) JAK2BTK
SCHEMBL10157243 0.76 ADRA2A (0.44) ALDH1A1MAP4K1MAPT
SCHEMBL21634896 0.76 NR3C2 (0.33) NR3C2MAP4K1
SCHEMBL17348473 0.76 NR3C2 (0.57) NR3C2MMP12PARP1SMN1; SMN2DRD2
SCHEMBL3489583 0.73 NR3C2 (0.55) NR3C2MMP12PARP1SMN1; SMN2MTNR1A
SCHEMBL15052400 0.73 NR3C2 (0.55) NR3C2MMP12PARP1DRD2DRD4
SCHEMBL12703333 0.71 LPL (0.42) JAK2BTKMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3768675-B1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORP (KR) 2026-04-01 EP disclosed
US-12037342-B2 Substituted eneoxindoles and uses thereof GILEAD SCIENCES, INC. (US) 2024-07-16 US disclosed
US-11780830-B2 Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2023-10-10 US disclosed
US-20230183262-A1 SUBSTITUTED ENEOXINDOLES AND USES THEREOF GILEAD SCIENCES, INC. 2023-06-15 US disclosed
US-11453681-B2 Substituted eneoxindoles and uses thereof GILEAD SCIENCES, INC. (US) 2022-09-27 US disclosed
EP-3972695-A1 SUBSTITUTED EXO-METHYLENE-OXINDOLES WHICH ARE HPK1/MAP4K1 INHIBITORS Gilead Sciences, Inc. (US) 2022-03-30 EP disclosed
US-20210317110-A1 TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2021-10-14 US disclosed
US-10995086-B2 Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2021-05-04 US disclosed
US-20200392153-A1 SUBSTITUTED ENEOXINDOLES AND USES THEREOF GILEAD SCIENCES, INC. 2020-12-17 US disclosed
WO-2020237025-A1 SUBSTITUTED EXO-METHYLENE-OXINDOLES WHICH ARE HPK1/MAP4K1 INHIBITORS GILEAD SCIENCES, INC. (US) 2020-11-26 WO disclosed
CN-111886233-A Novel triazolone derivative or salt thereof and pharmaceutical composition comprising the same 柳韩洋行 2020-11-03 CN disclosed
US-20190322655-A1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2019-10-24 US disclosed
US-20100094000-A1 PYRAZOLE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-15 US disclosed
US-20100094000-A1 PYRAZOLE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-15 US disclosed
US-20100094000-A1 PYRAZOLE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190322655-A1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME SLC10A1, VAPB, VAT1 NR3C2 1748/4885MMP12 2653/4885PARP1 4424/4885
US-20210317110-A1 TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME SLC10A1, VAT1, LIPC NR3C2 1951/4885MMP12 2261/4885PARP1 3385/4885
US-11780830-B2 Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same SLC10A1, VAT1, LIPC NR3C2 1951/4885MMP12 2261/4885PARP1 3385/4885
US-11453681-B2 Substituted eneoxindoles and uses thereof HIPK1, HPGDS, HIPK3 NR3C2 2311/4885MMP12 4189/4885PARP1 1641/4885
US-20230183262-A1 SUBSTITUTED ENEOXINDOLES AND USES THEREOF HIPK1, HPGDS, HIPK3 NR3C2 2311/4885MMP12 4189/4885PARP1 1641/4885
US-12037342-B2 Substituted eneoxindoles and uses thereof HIPK1, HPGDS, HIPK3 NR3C2 2311/4885MMP12 4189/4885PARP1 1641/4885
US-10995086-B2 Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same SLC10A1, VAT1, VAPB NR3C2 1856/4885MMP12 2597/4885PARP1 3485/4885
US-20100094000-A1 PYRAZOLE COMPOUNDS NR3C2, MC2R, NR3C1 NR3C2 1/4885MMP12 1824/4885PARP1 4374/4885
US-20200392153-A1 SUBSTITUTED ENEOXINDOLES AND USES THEREOF HIPK1, HPGDS, HIPK3 NR3C2 2311/4885MMP12 4189/4885PARP1 1641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.